TaiGen Biotechnology Co., Ltd.

太景 黃國龍總經理

Chairman & CEO: Philip Kuo-Lung Huang
Founded Date: 2001/04/30 
Tel: 886-2-8177-7020
Fax: 886-2-2796-3606 
Address: 7F, 138 Shin Ming Rd. Neihu Dist.,Taipei, Taiwan 114 R.O.C.
Website: http://www.taigenbiotech.com/


Company Profile:

Founded in 2001, TaiGen Biotechnology Co., Ltd. (“TaiGen Taiwan” or “TaiGen”) is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases. TaiGen has a wholly-owned Beijing subsidiary with a proven capacity to conduct clinical trials and related registrations. There are 66 FTEs including 80% R&D staffs in Taipei and Beijing offices.

TaiGen has built a fully-integrated pharmaceutical company by pursuing a business strategy that capitalizes on the management team's extensive expertise in drug discovery, development, global regulatory approval processes, and commercialization in China. Senior executives at TaiGen were recruited from both major pharmaceutical/biotech companies in the West as well as from Asian-based multinational companies. This unique expertise allows the company to focus on in-licensing innovative drugs targeting Asian-prevalent diseases to complement its own internal research programs as well as to partner its organic drug development programs.

TaiGen established an operation platform in the Greater China sustaining product development, sales and marketing. With the resources and strengths of partners and new business models, TaiGen’s value maximized. Through this business model, TaiGen successfully partnered Taigexyn® over 30 countries worldwide and will expand licensing territory.

TaiGen's current pipeline includes "first-in-class" and "best-in-class" products with worldwide IP rights.

Product Pipeline:

Taigen  2019 pipeline EN